Stable angina pectoris of coronary heart disease
Conditions
Interventions
Experimental group:Dan Lou tablet flavoring combined with conventional western medicine treatment
Control group:Conventional western medicine treatment
Sponsors
Liao'ning University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Meet the diagnostic criteria of Western medicine 2.4(2) Diagnostic criteria for stable angina, Diagnostic criteria for chest bi-syndrome with the syndrome of turbid phlegm and blood stasis and have no conflict with the efficacy of Danlou tablets; 2. Aged from 35-75 years old; 3. Those who have not taken any TCM preparation within two weeks; 4. Those who can provide personal contact information and cooperate with the clinical trial visit and follow-up; 5. Those who voluntarily participate in clinical observations and sign informed consent form.
Exclusion criteria
Exclusion criteria: 1. Stable angina complicated with valvular heart disease, various types of cardiomyopathy, malignant arrhythmia; The patients with heart failure whose NYHA cardiac function grading is III-IV; 2. Stable angina complicated with hypertension without treatment or uncontrolled hypertension (Bp=180/110mmHg); 3. Stable angina complicated with severe cerebrovascular disease; 4. Stable angina complicated with severe pulmonary insufficiency (PaO2<60mmHg), endocrine and hematopoietic systems severe primary disease, Moderate to severe hepatic insufficiency(Transaminase levels are 3 times higher than the upper limit of normal) or Moderate to severe renal insufficiency(eGFR<60ml/min/1.73m2) or patients with newly diagnosed acute; 5. Stable angina complicated with cerebrovascular disease during the past 3 months; 6. Stable angina complicated with psychosis; 7. Stable angina patient who are in the period of gestation or lactation; 8. Stable angina patient participated in other clinical trials in the past 3 months; 9. Patient with a life expectancy lower than 1 year; 10. Allergic patients or patients who are allergic to TCM treatment; 11. Those who are unwilling or unable to accept clinical follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency of angina pectoris; | — |
Secondary
| Measure | Time frame |
|---|---|
| Electrocardiogram;Serum differential endogenous products;MMP-9;Hemorheology;Echocardiography;Ang I;Exercise test;Seattle Angina Questionnaire;MPO;VCAM-1;IL-6;Hcy;Score of TCM symptoms;Anginal frequency;Blood glucose;Hs-CRP;Blood fat;Four coagulation; | — |
Countries
China
Contacts
Public ContactZhang Mingxue
Liao'ning University of Traditional Chinese Medicine
Outcome results
None listed